Sage Journals: Discover world-class research

Abstract

Spanish

French

BACKGROUND

The effectiveness and safety of warfarin require maintaining an international normalized ratio (INR) within the therapeutic range.

OBJECTIVE

To identify predictors of nontherapeutic INR results in patients receiving warfarin.

METHODS

A retrospective study was conducted using 350 ambulatory care patients from a broad geographic region, all receiving long-term warfarin therapy and followed in a tertiary-care cardiology clinic. Possible predictors of nontherapeutic INR results (gender, age, body weight, body mass index, height, race, tobacco use, alcohol use, warfarin dose, therapeutic indication, regimen intensity, INR monitoring frequency/category, interacting medications, adverse events) were assessed with logistic regression models. Subset analysis involved 146 patients concurrently monitored with capillary whole blood INR (CoaguChek).

RESULTS

As measured on venous specimens, 52% (182/350) of the patients had subtherapeutic INR results and 13% (44/350) had supratherapeutic INR results despite frequent (≤4 wk) monitoring in 75% of the patients. Due to the small sample size, supratherapeutic INR results could not be further analyzed. Of 19 predictors tested, only daily warfarin dose (p < 0.02) and regimen intensity (p < 0.03) were significant independent and additive predictors of subtherapeutic results. Patients on the high-intensity regimen (INR 2.5–3.5) and receiving warfarin ≤6 mg/day had >50% risk of having subtherapeutic INR results. Subtherapeutic CoaguChek results were independent predictors of subtherapeutic venipuncture INR results in the subset (p = 0.001).

CONCLUSIONS

In the absence of readily identifiable predictors, only higher warfarin dosing and/or more frequent monitoring (possibly with point-of-care/home monitoring devices) may minimize the time that INRs are subtherapeutic, especially in patients receiving low-dose and/or high-intensity anticoagulation therapy.

Keywords

warfarin monitoring predictors atrial fibrillation mechanical heart valve replacement

Get full access to this article

View all access options for this article.

References

1. Community practice. Drug Topics 2004;149:25–6.

2. Salem

Stein

Al-Ahmad

Bussey

Horstkotte

Miller

Antithrombotic therapy in valvular heart disease—native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):457S–82S.

3. Singer

Albers

Dalen

Halperin

Manning

WJ.

Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):429S–56S.

4. O'Donnell

Hirsh

Establishing an optimal therapeutic range for coumarins: filling in the gaps. Arch Intern Med 2004;164:588–90.

5. Hylek

Chang

Skates

Hughes

Singer

DE.

Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000;160:1612–7.

6. Applied logistic regression. In: Hosmer

Lemeshow

, eds. New York: John Wiley & Sons, 1989:82–118.

7. Sawicki

PT.

A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working group for the study of patient self-management of oral anticoagulation. JAMA 1999;281:145–50.

8. Hirsh

Dalen

Anderson

Poller

Bussey

Ansell

Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(1 suppl):8S–21S.

9. Bungard

Ghali

Teo

McAlister

Tsuyuki

RT.

Why do patients with atrial fibrillation not receive warfarin?

Arch Intern Med 2000;160:41–6.

10.

10. Stafford

Singer

DE.

National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996;156:2537–41.

11.

11. Peterson

Boom

Jackson

Vial

JH.

Doctors' beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention. Intern Med J 2002;32:15–23.

12.

12. Cohen

Almoznino-Sarafian

Alon

Gorelik

Koopfer

Chachashvily

Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke 2000;31:1217–22.

13.

13. McCrory

Matchar

Samsa

Sanders

Pritchett

EL.

Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995;155:277–81.

14.

14. Hylek

Skates

Sheehan

Singer

DE.

An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540–6.

15.

15. Horstkotte

Piper

Wiemer

Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis 1998;5(suppl 1):19–24.

16.

16. McBane

2nd Felty

Hartgers

Chaudhry

Beyer

Santrach

PJ.

Importance of device evaluation for point-of-care prothrombin time international normalized ratio testing programs. Mayo Clin Proc 2005;80:181–6.

17.

17. Gosselin

Owings

White

Hutchinson

Branch

Mahackian

A comparison of point-of-care instruments designed for monitoring oral anticoagulation with standard laboratory methods. Thromb Haemost 2000;83:698–703.

18.

18. Ansell

Hamke

Holden

Knapic

Cost effectiveness of monitoring warfarin therapy using standard versus capillary prothrombin times. Am J Clin Pathol 1989;91:587–9.

19.

19. Chapman

Stephens

Hamann

Bailey

Dorko

CS.

Accuracy, clinical correlation, and patient acceptance of two handheld prothrombin time monitoring devices in the ambulatory setting. Ann Pharmacother 1999;33:775–80. DOI 10.1345/aph.18317.

20.

20. Samsa

Matchar

DB.

Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis 2000;9:283–92.

21.

21. Hope

Havrda

DE.

Subtherapeutic INR values associated with a switch to generic warfarin. Ann Pharmacother 2001;35:183–7. DOI 10.1345/aph.10207.

22.

22. Howard

Ellerbeck

Engelman

Patterson

KL.

The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf 2002;11:569–76.

23.

23. Miller

LG.

Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharm 1990;9:125–35.

24.

24. Colucci

Knapp

JF.

Increase in international normalized ratio associated with smoking cessation (letter). Ann Pharmacother 2001;35:385–6. DOI 10.1345/aph.10226.

25.

25. Cropp

Bussey

HI.

A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 1997;17:917–28.

26.

26. Wilkinson

GR.

Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352:2211–21.

27.

27. Absher

Moore

Parker

MH.

Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 2002;36:1512–7. DOI 10.1345/aph.1C025.

28.

28. Johnson

Wootton

Kimzey

McCullagh

Wesley

Byrd

Use of herbal therapies by adults seen in an ambulatory care research setting: an exploratory survey. J Altern Complement Med 2000;6:429–35.

Search for Predictors of Nontherapeutic INR Results with Warfarin Therapy

Abstract

BACKGROUND

OBJECTIVE

METHODS

RESULTS

CONCLUSIONS

Keywords

Get full access to this article

References